NTLA
Intellia Therapeutics, Inc.
Biotechnology · Healthcare · United States
12.47
close · 2026-10-30
value
20
cheaper than peers20
quality
18
stronger fundamentals18
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 2.40× | 64 |
| earnings yield, latest year | -30.6% | 34 |
| earnings yield, 2 years ago | -43.5% | 33 |
| cash flow yield, 1 year ago | -20.3% | 33 |
| cash flow yield, latest year | -22.7% | 32 |
| cash flow yield, 2 years ago | -23.4% | 32 |
| earnings yield, 3 years ago | -49.4% | 31 |
| price to sales | 29.36× | 31 |
| earnings yield, 1 year ago | -42.1% | 30 |
| cash flow yield, 3 years ago | -22.4% | 27 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 13.0% | 56 |
| return on equity | -56.3% | 45 |
| revenue growth | -46.2% | 19 |
| operating margin | -1472.3% | 17 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$235.2M |
| employees | 377 |
| first trade | 2016-05-06 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.81 | -5.25 | -5.42 | -6.16 |
| free cash flow | -$395.9M | -$354.7M | -$408.1M | -$391.7M |
| net income | -$412.7M | -$519.0M | -$481.2M | -$474.2M |
| revenue | $67.7M | $57.9M | $36.3M | $52.1M |
| unusual items | -$899,000 | -$32.6M | -$100,000 | -$13.5M |